Zogenix’s Stand-alone Hydrocodone To Stand Before Advisory Panel
This article was originally published in The Pink Sheet Daily
If approved, Zohydro will be the first extended-release version of hydrocodone and the first not to be combined with other painkillers.
You may also be interested in...
FDA will extend user fee goal dates as needed to account for the loss of two days in review cycles resulting from the government office shutdown. The extreme weather conditions led to cancellation of three advisory committees during the week of Oct. 29.
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.